Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 2/2017

10.06.2016 | Focussed Research Review

Using natural products to promote caspase-8-dependent cancer cell death

verfasst von: Poonam Tewary, A. A. Leslie Gunatilaka, Thomas J. Sayers

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The selective killing of cancer cells without toxicity to normal nontransformed cells is an idealized goal of cancer therapy. Thus, there has been much interest in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a protein that appears to selectively kill cancer cells. TRAIL has been reported to trigger apoptosis and under some circumstances, an alternate death signaling pathway termed necroptosis. The relative importance of necroptosis for cell death induction in vivo is under intensive investigation. Nonetheless, many cancer cells (particularly those freshly isolated from cancer patients) are highly resistant to TRAIL-mediated cell death. Therefore, there is an underlying interest in identifying agents that can be combined with TRAIL to improve its efficacy. There are numerous reports in which combination of TRAIL with standard antineoplastic drugs has resulted in enhanced cancer cell death in vitro. However, many of these chemotherapeutic drugs are nonspecific and associated with adverse effects, which raise serious concerns for cancer therapy in patients. By contrast, natural products have been shown to be safer and efficacious alternatives. Recently, a number of studies have suggested that certain natural products when combined with TRAIL can enhance cancer cell death. In this review, we highlight molecular pathways that might be targeted by various natural products to promote cell death, and focus on our recent work with withanolides as TRAIL sensitizers. Finally, we will suggest synergistic approaches for combining active withanolides with various forms of immunotherapy to promote cancer cell death and an effective antitumor immune response.
Literatur
1.
Zurück zum Zitat Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B (1995) The biochemistry of programmed cell-death. Faseb J 9(13):1277–1287PubMed Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B (1995) The biochemistry of programmed cell-death. Faseb J 9(13):1277–1287PubMed
3.
Zurück zum Zitat Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, Santacroce R, Di Corcia MG, Lucchese A, Dini L, Pani P, Santacroce S, Simone S, Bucci R, Farber E (2002) Cell death: apoptosis versus necrosis (review). Int J Oncol 21(1):165–170PubMed Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, Santacroce R, Di Corcia MG, Lucchese A, Dini L, Pani P, Santacroce S, Simone S, Bucci R, Farber E (2002) Cell death: apoptosis versus necrosis (review). Int J Oncol 21(1):165–170PubMed
6.
Zurück zum Zitat Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22(53):8628–8633CrossRefPubMed Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22(53):8628–8633CrossRefPubMed
9.
Zurück zum Zitat Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL (2013) On the TRAIL to successful cancer therapy. Predicting and counteracting resistance against TRAIL based therapeutics. Oncogene 32(11):1341–1350. doi:10.1038/onc.2012.164 CrossRefPubMed Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL (2013) On the TRAIL to successful cancer therapy. Predicting and counteracting resistance against TRAIL based therapeutics. Oncogene 32(11):1341–1350. doi:10.​1038/​onc.​2012.​164 CrossRefPubMed
12.
Zurück zum Zitat Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S (1805) Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 2:123–140. doi:10.1016/j.bbcan.2009.11.004 Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S (1805) Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 2:123–140. doi:10.​1016/​j.​bbcan.​2009.​11.​004
14.
Zurück zum Zitat Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, Strasser A, Kaufmann T (2009) XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460(7258):1035–1039. doi:10.1038/nature08229 CrossRefPubMedPubMedCentral Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, Strasser A, Kaufmann T (2009) XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460(7258):1035–1039. doi:10.​1038/​nature08229 CrossRefPubMedPubMedCentral
15.
18.
Zurück zum Zitat He WY, Wang Q, Xu J, Xu XL, Padilla MT, Ren GS, Gou X, Lin Y (2012) Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2-and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy 8(12):1811–1821. doi:10.4161/auto.22145 CrossRefPubMedPubMedCentral He WY, Wang Q, Xu J, Xu XL, Padilla MT, Ren GS, Gou X, Lin Y (2012) Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2-and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy 8(12):1811–1821. doi:10.​4161/​auto.​22145 CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS, Sethi G (2015) Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood) 240(6):760–773. doi:10.1177/1535370215579167 CrossRef Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS, Sethi G (2015) Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood) 240(6):760–773. doi:10.​1177/​1535370215579167​ CrossRef
26.
Zurück zum Zitat Booth NL, Sayers TJ, Brooks AD, Thomas CL, Jacobsen K, Goncharova EI, McMahon JB, Henrich CJ (2009) A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol Immunother 58(8):1229–1244. doi:10.1007/s00262-008-0637-8 CrossRefPubMed Booth NL, Sayers TJ, Brooks AD, Thomas CL, Jacobsen K, Goncharova EI, McMahon JB, Henrich CJ (2009) A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol Immunother 58(8):1229–1244. doi:10.​1007/​s00262-008-0637-8 CrossRefPubMed
28.
Zurück zum Zitat Henrich CJ, Brooks AD, Erickson KL, Thomas CL, Bokesch HR, Tewary P, Thompson CR, Pompei RJ, Gustafson KR, McMahon JB, Sayers TJ (2015) Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation. Cell Death Dis. doi:10.1038/cddis.2015.38 PubMedPubMedCentral Henrich CJ, Brooks AD, Erickson KL, Thomas CL, Bokesch HR, Tewary P, Thompson CR, Pompei RJ, Gustafson KR, McMahon JB, Sayers TJ (2015) Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation. Cell Death Dis. doi:10.​1038/​cddis.​2015.​38 PubMedPubMedCentral
32.
Zurück zum Zitat Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, Cain K, MacFarlane M, Hacker G, Leverkus M (2011) cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 43(3):449–463. doi:10.1016/j.molcel.2011.06.011 CrossRefPubMedPubMedCentral Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, Cain K, MacFarlane M, Hacker G, Leverkus M (2011) cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 43(3):449–463. doi:10.​1016/​j.​molcel.​2011.​06.​011 CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P (2011) The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 43(3):432–448. doi:10.1016/j.molcel.2011.06.006 CrossRefPubMed Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P (2011) The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 43(3):432–448. doi:10.​1016/​j.​molcel.​2011.​06.​006 CrossRefPubMed
34.
40.
Zurück zum Zitat Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006) TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176(8):4894–4901CrossRefPubMed Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006) TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176(8):4894–4901CrossRefPubMed
42.
Zurück zum Zitat Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G (2010) Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ 17(6):942–951. doi:10.1038/cdd.2009.190 CrossRefPubMed Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G (2010) Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ 17(6):942–951. doi:10.​1038/​cdd.​2009.​190 CrossRefPubMed
43.
Zurück zum Zitat Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pacheco Y, Salaun B, Renno T, Micheau O, Lebecque S (2012) dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ 19(9):1482–1494. doi:10.1038/cdd.2012.22 CrossRefPubMedPubMedCentral Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pacheco Y, Salaun B, Renno T, Micheau O, Lebecque S (2012) dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ 19(9):1482–1494. doi:10.​1038/​cdd.​2012.​22 CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Lee S, Yagita H, Sayers TJ, Celis E (2010) Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. Cancer Immunol Immun 59(7):1073–1081. doi:10.1007/s00262-010-0834-0 CrossRef Lee S, Yagita H, Sayers TJ, Celis E (2010) Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. Cancer Immunol Immun 59(7):1073–1081. doi:10.​1007/​s00262-010-0834-0 CrossRef
45.
Zurück zum Zitat Krown SE, Kerr D, Stewart WE, Field AK, Oettgen HF (1985) Phase-I trials of poly(I, C) complexes in advanced cancer. J Biol Resp Modif 4(6):640–649 Krown SE, Kerr D, Stewart WE, Field AK, Oettgen HF (1985) Phase-I trials of poly(I, C) complexes in advanced cancer. J Biol Resp Modif 4(6):640–649
47.
Zurück zum Zitat Navabi H, Jasani B, Reece A, Clayton A, Tabi Z, Donninger C, Mason M, Adams M (2009) A clinical grade poly I:C-analogue (Ampligen (R)) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27(1):107–115. doi:10.1016/j.vaccine.2008.10.024 CrossRefPubMed Navabi H, Jasani B, Reece A, Clayton A, Tabi Z, Donninger C, Mason M, Adams M (2009) A clinical grade poly I:C-analogue (Ampligen (R)) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27(1):107–115. doi:10.​1016/​j.​vaccine.​2008.​10.​024 CrossRefPubMed
50.
Zurück zum Zitat Swers JS, Grinberg L, Wang L, Feng H, Lekstrom K, Carrasco R, Xiao Z, Inigo I, Leow CC, Wu H, Tice DA, Baca M (2013) Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis. Mol Cancer Ther 12(7):1235–1244. doi:10.1158/1535-7163.Mct-12-1107 CrossRefPubMed Swers JS, Grinberg L, Wang L, Feng H, Lekstrom K, Carrasco R, Xiao Z, Inigo I, Leow CC, Wu H, Tice DA, Baca M (2013) Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis. Mol Cancer Ther 12(7):1235–1244. doi:10.​1158/​1535-7163.​Mct-12-1107 CrossRefPubMed
Metadaten
Titel
Using natural products to promote caspase-8-dependent cancer cell death
verfasst von
Poonam Tewary
A. A. Leslie Gunatilaka
Thomas J. Sayers
Publikationsdatum
10.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 2/2017
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1855-0

Weitere Artikel der Ausgabe 2/2017

Cancer Immunology, Immunotherapy 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.